519 related articles for article (PubMed ID: 33879893)
21. Prognostic value of baseline
Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
[TBL] [Abstract][Full Text] [Related]
22. Pre-Therapeutic Total Lesion Glycolysis on [
Mayerhoefer ME; Staudenherz A; Kiesewetter B; Weber M; Simonitsch-Klupp I; Gibbs P; Dolak W; Lukas J; Raderer M
Mol Imaging Biol; 2019 Dec; 21(6):1192-1199. PubMed ID: 30847823
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
[TBL] [Abstract][Full Text] [Related]
24. [The correlation between metabolic parameters in (18)F-FDG PET-CT and solid and micropapillary histological subtypes in lung adenocarcinoma].
Guo Y; Yao ZM; Chen M; Chen CX
Zhonghua Zhong Liu Za Zhi; 2022 Jun; 44(6):555-561. PubMed ID: 35754230
[No Abstract] [Full Text] [Related]
25.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
26. Primary tumor standardized uptake value (SUVmax) measured on
Hui Z; Wei F; Ren H; Xu W; Ren X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.
Lee HJ; Lee JJ; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
J Gynecol Oncol; 2017 Jul; 28(4):e43. PubMed ID: 28541634
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
29. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
31. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
32. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
33. Relationship between
Bu L; Tu N; Wang K; Zhou Y; Xie X; Han X; Lin H; Feng H
Korean J Radiol; 2022 Jan; 23(1):112-123. PubMed ID: 34983098
[TBL] [Abstract][Full Text] [Related]
34. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic Value of
Su JM; Zheng QZ; Huang WR; Deng J; Wu J; Lu HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1181-1186. PubMed ID: 34362500
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of pretreatment volume-based quantitative
Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of FDG PET/CT in Patients With Neuroendocrine Carcinoma of the Uterine Cervix.
Jiang Y; Hou G; Li F; Zhu Z; Cheng W
Clin Nucl Med; 2021 Dec; 46(12):971-976. PubMed ID: 34619703
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of multiple metabolic and heterogeneity parameters of
Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
[TBL] [Abstract][Full Text] [Related]
39. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of baseline
Dondi F; Albano D; Bellini P; Cerudelli E; Treglia G; Bertagna F
Clin Imaging; 2023 Feb; 94():71-78. PubMed ID: 36495848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]